期刊
FUTURE ONCOLOGY
卷 15, 期 31, 页码 3555-3563出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2019-0380
关键词
apheresis; autologous hematopoietic cell transplantation; CXCR4/SDF-1 signaling; multiple myeloma; stem cell mobilization
类别
资金
- NIH/NCI [R35: 1R35CA210084]
- BioLineRx Ltd Modi'inMaccabim-Re'ut, Israel
Effective hematopoietic cell transplantation relies upon collecting adequate numbers of CD34(+) hematopoietic stem cells, typically from peripheral blood. A minimum of >= 2 x 10(6) CD34(+) cells/kg are necessary, while transplants of >= 5-6 x 10(6) CD34(+) cells/kg are associated with improved hematopoietic recovery. Granulocyte colony stimulating factor (G-CSF) remains the gold standard for hematopoietic stem cell mobilization. However, in randomized trials for autologous-hematopoietic cell transplantation in multiple myeloma, approximately 45% of patients remain unable to optimally mobilize with G-CSF alone despite multiple injections and apheresis days. Therefore, reducing mobilization failures remains an unmet need. The study objective is to evaluate the superiority of one dose of BL-8040 plus G-CSF over placebo plus G-CSF to mobilize >= 6.0 x 10(6) CD34(+) cells/kg in up to two apheresis days.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据